UK Stocks That May Be Trading Below Their Estimated Value
As the FTSE 100 and FTSE 250 indices face downward pressure from weak trade data out of China, investors in the United Kingdom are closely monitoring global economic cues that have impacted commodity prices and corporate earnings. In this environment, identifying stocks that may be trading below their estimated value can offer potential opportunities for investors seeking to navigate market volatility while focusing on long-term fundamentals.
Name
Current Price
Fair Value (Est)
Discount (Est)
AstraZeneca (LSE:AZN)
£100.22
£191.51
47.7%
Dr. Martens (LSE:DOCS)
£0.5945
£1.13
47.3%
Aptitude Software Group (LSE:APTD)
£2.96
£5.15
42.6%
Gooch & Housego (AIM:GHH)
£4.71
£8.99
47.6%
Victorian Plumbing Group (AIM:VIC)
£0.808
£1.41
42.5%
Informa (LSE:INF)
£7.986
£15.26
47.7%
Duke Capital (AIM:DUKE)
£0.285
£0.54
47.3%
Huddled Group (AIM:HUD)
£0.0325
£0.065
49.9%
Vistry Group (LSE:VTY)
£6.134
£11.34
45.9%
Deliveroo (LSE:ROO)
£1.75
£3.08
43.1%
Click here to see the full list of 48 stocks from our Undervalued UK Stocks Based On Cash Flows screener.
Let's dive into some prime choices out of the screener.
Overview: Restore plc, with a market cap of £338.20 million, offers services to offices and workplaces in both the public and private sectors primarily in the United Kingdom.
Operations: The company's revenue segments consist of Datashred (£36 million), Technology (£36.10 million), Harrow Green (£35.30 million), and Information Management (£167.90 million).
Estimated Discount To Fair Value: 38.8%
Restore is trading at £2.47, significantly below its estimated fair value of £4.04, suggesting it may be undervalued based on cash flows. The company recently reported a net income of £12.4 million for 2024, rebounding from a loss the previous year. Earnings are forecast to grow at 24.8% annually, outpacing the UK market's growth rate and indicating strong future potential despite an unstable dividend history and lower revenue growth expectations relative to earnings growth.
The growth report we've compiled suggests that Restore's future prospects could be on the up.
Dive into the specifics of Restore here with our thorough financial health report.
Overview: Dr. Martens plc designs, develops, procures, markets, sells, and distributes footwear under the Dr. Martens brand and has a market cap of approximately £573.81 million.
Operations: The company's revenue is primarily derived from its footwear segment, totaling £805.90 million.
Estimated Discount To Fair Value: 47.3%
Dr. Martens is trading at £0.59, below its estimated fair value of £1.13, highlighting potential undervaluation based on cash flows. Despite a lower profit margin this year compared to last, earnings are expected to grow significantly at 39.72% annually over the next three years, outpacing the UK market's growth rate of 14.1%. However, interest payments are not well covered by earnings and the dividend track record remains unstable.
Our earnings growth report unveils the potential for significant increases in Dr. Martens' future results.
Get an in-depth perspective on Dr. Martens' balance sheet by reading our health report here.
Overview: Vanquis Banking Group plc provides personal credit products to the non-standard lending market in the United Kingdom and the Republic of Ireland, with a market cap of £192.11 million.
Operations: The company's revenue is generated from several segments, including Cards (£238.10 million), Loans (£6.30 million), Vehicle Finance (£34.20 million), and Second Charge Mortgages (£1.70 million).
Estimated Discount To Fair Value: 24.8%
Vanquis Banking Group is trading at £0.75, below its estimated fair value of £1, suggesting potential undervaluation based on cash flows. Despite a significant net loss of £119.3 million in 2024, revenue is forecast to grow at 16.1% annually, outpacing the UK market's growth rate of 3.9%. However, the company's debt coverage by operating cash flow is weak and no final dividend was recommended for the financial year ended December 2024.
According our earnings growth report, there's an indication that Vanquis Banking Group might be ready to expand.
Take a closer look at Vanquis Banking Group's balance sheet health here in our report.
Gain an insight into the universe of 48 Undervalued UK Stocks Based On Cash Flows by clicking here.
Got skin in the game with these stocks? Elevate how you manage them by using Simply Wall St's portfolio, where intuitive tools await to help optimize your investment outcomes.
Streamline your investment strategy with Simply Wall St's app for free and benefit from extensive research on stocks across all corners of the world.
Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include AIM:RST LSE:DOCS and LSE:VANQ.
This article was originally published by Simply Wall St.
Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@simplywallst.com
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 hours ago
- Yahoo
London must ‘market its successes better' to avoid another Wise
Britain must emulate the success of Nasdaq and get better at trumpeting its business success stories if it wants to attract more companies to list in London, one of the UK's top fintech venture capital investors has said. Speaking to City AM the day that payments darling Wise revealed plans to ditch its primary listing for New York, Anthemis founder Amy Nauiokas said the London Stock Exchange (LSE) should try emulate the support promotion the US's tech-heavy bourse gives its new constituents. 'It's not brain surgery,' said Nauiokas, whose firm has been an early-stage backer of fintech success stories like Etoro, Zoopla and Tide. 'They [the LSE] need to promise UK entrepreneurs that there's a path here, and that they'll support them, build an ecosystem around them, and give the perks that the Nasdaq gives them.' London capital markets have been locked in a multi-year struggle to attract and retain some of its brightest companies. Since the start of 2024 alone, cherished listed firms like Darktrace, TUI and most DS Smith have all delisted or been taken private from the capital's stock market. And promising UK-headquartered scale-ups like Arm have opted to list in New York over London, with other darlings like Revolut and Klarna looking likely to follow suit. Departed firms have tended to cite London's stubbornly low valuations and lower liquidity relative to its US rivals, but Nauiokas argued that the lengths to which New York goes to promote and celebrate its new additions was just as important a factor. Commenting on the Nasdaq's custom of advertising its fresh listings in New York's Time Square, she said: 'Half the reason why people go there is so they get to see their their picture on 45th Street.' Her comments ring true with the rationale for ditching London given by Wise, which floated in the UK to great fanfare in 2021. Billionaire cofounder Kristo Kaarmannder said a US listing would help raise Wise's profile in the country as it joins the many London-based fintech giants looking to expand their services in the world's largest market. 'We believe the addition of a primary US listing would help us accelerate our mission and bring substantial strategic and capital market benefits to Wise and our owners,' he said in the firm's statement announcing its planned departure. Nauiokas, whose firm invests in start-ups in both the US and UK with offices in both New York and London, said she understood the Wise board's decision, adding that were she a secondary capital and pre-IPO dealmaker, she 'would probably say the best option right now was either a dual listing or a US-based IPO'. But despite the downbeat rhetoric surrounding the London Stock Exchange, she added that the ongoing political turmoil in America was something on which London – and Europe as a whole – should be poised to capitalise. 'It strikes me that all the opportunity is here [in London],' she said. 'This is a moment. A moment for investors to find great entrepreneurs and make money, but also a moment for regulatory navel gazing – government navel gazing – private partnership navel gazing – to say we could do something here. Let's do something.' Family offices and institutional money are increasingly looking to reduce the weighting of US assets in their portfolio in response to the capricious and unpredictable policy directives from the White House, Nauiokas said. Many ultra-rich families have re-weighted their portfolios from an '80/20 North America to Europe to now 50/50'. 'I'm super excited about the UK specifically. But it needs to take this moment of market geopolitical dislocation,' she said, adding: 'The LSE can do a much better job of reshaping its proposition, and the government needs to get rid of stamp duty on shares.' Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
9 hours ago
- Yahoo
Up 20% in a week! This growth stock is on fire – should I consider buying it?
I'm looking to add a growth stock to my self-invested personal pension (SIPP). This marks a change in strategy for me. In recent years, I've focused on value shares, especially income-paying FTSE 100 financials like Legal & General Group. But I need a break from being a contrarian. Today, I want to piggyback on some momentum. Pick a red-hot growth share and, with luck, hope it climbs even higher. Naturally, both strategies carry risks. Value stocks can turn out to be traps, while high-flying growth shares can come crashing down. I'm especially wary of buying after a stock has already surged, which is exactly the case with a FTSE 250 company that's rocketed 20% in the last week. This isn't a flash in the pan though. Its shares are up more than 50% over 12 months and over 115% in five years. The stock in question is Chemring Group (LSE: CHG), and it has the benefit of operating in a sector that's very much in demand right now: defence. Chemring is a world leader in chemical and biological threat detection, electronic warfare and systems that locate improvised explosive devices. In today's uncertain world, its kit is in demand. It isn't the only one riding this trend. FTSE 100 peer Babcock International jumped 13% last week. BAE Systems and Rolls-Royce have also wowed lately. Happily, I hold both. Chemring got a major lift on Friday (6 June) when analysts at Berenberg upgraded the stock from Hold to Buy, citing a 'very bright' outlook to 2030. It pointed to a pipeline of opportunities in Chemring's energetics division. Berenberg noted that earnings per share are forecast to compound at 19% a year on average over the next three years. The broker called Chemring's price/earnings-to-growth (PEG) ratio 'undemanding', and hiked its price target from 470p to 670p. This came hot on the heels of a first-half update on Tuesday, when Chemring confirmed its annual guidance after reporting a 12% rise in underlying earnings to £39.8m. The order book hit a record £1.3bn, with intake up 42% to £488m. Management noted rising global tensions, from Ukraine and the Middle East to the Asia-Pacific, with many governments increasing their defence budgets and rushing to replenish depleted stockpiles. All this explains the recent rally, but even strong shares can run too far, too fast. There are five analyst forecasts for the stock, all with a 12-month target of 540p. That's almost 7% below today's price of 584p. However, all six analysts rating the stock currently label it a Strong Buy. None say Hold, none say Sell. After quickfire surge, Chemring may slip back slightly as profit takers emerge, so I'd wait and watch before diving in. At a price-to-earnings ratio of 36, it's hardly cheap. Personally, I already have plenty of exposure to defence through BAE and Rolls-Royce. If I wasn't already so heavily exposed to this dynamite sector, I'd seriously consider buying Chemring in the days ahead. There's still a chance I might, if the heat goes out of it a little. The post Up 20% in a week! This growth stock is on fire – should I consider buying it? appeared first on The Motley Fool UK. More reading 5 Stocks For Trying To Build Wealth After 50 One Top Growth Stock from the Motley Fool Harvey Jones has positions in BAE Systems and Rolls-Royce Plc. The Motley Fool UK has recommended BAE Systems, Chemring Group Plc, and Rolls-Royce Plc. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors. Motley Fool UK 2025 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
9 hours ago
- Yahoo
If I could only save one UK share in my SIPP, here's what it would be
No investor should gamble their future on just one UK share. That would be an almighty risk. My self-invested personal pension (SIPP) holds around 20 different stocks. While I would happily junk two or three of them (I'm looking at you Aston Martin, Glencore and Ocado Group), binning the rest would be painful. But let's say somebody put a gun to my head. Which would be the sole survivor? There are some stocks that investors might buy if they knew in advance they could only hold one. Utility stock National Grid is seen as a solid dividend growth play, but I don't actually hold it. Consumer goods giant Unilever has both defensive merits. I did hold that, but recently banked a profit as I was underwhelmed by its growth potential. So what about the stocks I do hold? Which would I save? I'd hate to sell private equity specialist 3i Group, which has doubled my money in 18 months. It's had a great run though, and looks a little bit too expensive, so it would have to go. I'd also hate to offload insurer Phoenix Group Holdings, whose shares are up 30% in a year, and still yield a bumper 8.3%. It's a happy day when the Phoenix dividend hits my SIPP, and the same applies for rival FTSE 100 wealth manager M&G. Another super-high yielder. Yet both would have to go. If those dividends are cut at any time, the investment case could collapse. I don't think they will, but the stakes are high here. I'd also offload my SIPP growth stock stars Rolls-Royce Holdings and BAE Systems. They've done brilliantly, but remember, I can only hold one stock here. I'd bank my profits on both to make way for last stock standing, Lloyds Banking Group (LSE: LLOY). I bought the high street bank on three occasions in 2023, and it's been the surprise over-achiever in my portfolio. I hoped for modest share price growth. Instead, Lloyd shares are up 40% in a year (and 72% since I bought them). Once my reinvested dividends are added, my total return is almost 100% in 18 months. Lloyds is now almost entirely focused on the UK domestic market, which makes it a play on our economic fortunes. There are good sides to that – but also bad ones. The UK economy isn't exactly thriving right now, while inflation remains a menace. Mortgage rates have actually been rising again in recent weeks, which could further squeeze house prices, and slow demand. Lloyds has also had to set aside hefty sums for potential debt impairments, and could be on the hook for a billion or two, following the motor finance mis-selling scandal. But despite its strong run, the Lloyds price doesn't look over valued, with a price-to-earnings ratio of just over 12. The forecast yield of 4.4% should keep the income flowing. Especially since it's covered 2.1 times by earnings. The bank is also running a hefty £1.7bn share buyback. Lloyd will have its ups and downs and like I said, I would be crazy to go all in on just one stock. But if I had to do it, this would be the one. The post If I could only save one UK share in my SIPP, here's what it would be appeared first on The Motley Fool UK. More reading 5 Stocks For Trying To Build Wealth After 50 One Top Growth Stock from the Motley Fool Harvey Jones has positions in 3i Group Plc, BAE Systems, Lloyds Banking Group Plc, M&g Plc, Phoenix Group Plc, and Rolls-Royce Plc. The Motley Fool UK has recommended BAE Systems, Lloyds Banking Group Plc, M&g Plc, National Grid Plc, Rolls-Royce Plc, and Unilever. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors. Motley Fool UK 2025 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
